The FDA transitioned the small-molecule inhibitor tepotinib (Tepmetko) from accelerated to full approval for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations.

Please provide your email address to receive an email when new articles are posted on . Tepotinib demonstrated robust response in long-term follow-up among patients with NSCLC with MET exon 14 ...

TOKYO and XIAMEN, China, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted priority review to tepotinib for the treatment of certain patients with non-small cell lung ...

PARIS -- More than half of EGFR-positive lung cancers that progressed on osimertinib (Tagrisso) responded to the MET inhibitor tepotinib (Tepmetko) plus additional osimertinib, according to a ...

Dr Shobhit Baijal, Consultant Medical Oncologist, University Hospital Birmingham NHS Trust explains: “Existing treatment options for patients with METex14 skipping mutations have generally shown ...

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a ...

ROCKLAND, Mass., March 25, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the Japanese Ministry of Health, ...

Japan’s medicines regulator has approved Merck KGaA’s oral MET inhibitor tepotinib for non-small cell lung cancer with MET exon 14 (METex14) mutations, which occur in 3% to 5% of all NSCLC cases. The ...

Dexamethasone for the prevention of transcatheter arterial chemoembolization-induced fever, nausea, vomiting, and anorexia in patients with hepatocellular carcinoma: A randomized, double-blind, ...

HOUSTON -- Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as ...

NICE has recommended tepotinib within its marketing authorisation, as an option for treating advanced non-small-cell lung cancer (NSCLC) with METex14 skipping alterations in adults, only if the ...